In conclusion, the research conducted by the authors demonstrated that atorvastatin can improve pulmonary vascular inflammation and pulmonary vascular remodeling in COPD to a certain extent, possibly by increasing the expression level of HDAC2, inhibiting the expression of inflammation-related genes, and reducing the release of the inflammatory factor pulmonary vascular endothelial factor. The gene discussed is HDAC2; the disease is chronic obstructive pulmonary disease.